Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(1.18) per share which missed the analyst consensus estimate of $(1.11) by 6.31 percent. This is a 18 percent decrease over losses of $(1.00) per share from the same period last year. The company reported quarterly sales of $490.000 thousand which missed the analyst consensus estimate of $16.370 million by 97.01 percent. This is a 94.21 percent decrease over sales of $8.466 million the same period last year.